New Delhi: Shilpa Biologicals Pvt Ltd (SBPL), a wholly-owned subsidiary of Shilpa Medicare, on Monday entered into a three-year definitive agreement with Dr Reddy’s Laboratories Ltd (DRL) for the production-supply of the Sputnik V vaccine.
The targeted production of the dual vector Sputnik V for the fIrst 12 months is 50 million doses (50 million of Component 1 and 50 million of component 2), from the date of start of commercial production, Shilpa Medicare said in an exchange filing.
DRL has partnered with HVI/RDIF for clinical development of the vaccine and has distribution rights in geographies including India. DRL will facilitate the transfer of the sputnik technology to SBPL.
Under the agreement, SBPL will be responsible for manufacture of the vaccine, while DRL is responsible for distribution/marketing of the vaccine in its marketing territories.
The companies are also exploring the option to manufacture Sputnik Light, a single dose version of the vaccine in the near future, it said.
